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SUMMARY
After establishing accuracy requirements for in vivo dosimetry in total body irradiation, the
technical and systematical limitations of the commonly used detectors are summarized. The potential
of this tool for quality assurance is demonstrated by the results of in vivo measurements with two
different photon energies.
INTRODUCTION
Although in vivo dosimetry plays a minor
role in the whole field of radiation therapy, it has
a distinctive importance in total body irradiation
(TBI). After an inquiry at European
radiooncologic centres [Quast, 1987]
a majority of them uses in vivo dosimetry for
different purposes in TBI. Some groups use in
vivo dosimetry for localization, dose distribution
calculation and modification during fractionized
TBI treatments instead of prior localisation, basic
dosimetry and treatment planning. Most groups
however prefer it for treatment verification or
quality assurance in a broader sense.
An important reason for the use of in
vivo dosimetry in TBI is the complex and
irregular target volume, which renders a reliable
dose calculation based on simple basic phantom
measurements more difficult. Furthermore some
authors [Christ et ai, 1991] point out that in TBI a
high dose is delivered in a relative short time.
Therefore it is usually not possible to correct
faulty procedures.
ACCURACY REQUIREMENTS
A first orientation concerning the
required accuracy of in vivo dosimetry in TBI is
provided by generally accepted or recommended
dose variations in the irradiated target volume.
After the International Commission on Radiation
Units and Measurements (ICRU) [ICRU, 1993]
the heterogeneity of the dose distribution within
the planning target volume should be kept within
+7% and -5% of prescribed dose. This is a rather
rigorous demand regarding the irregular target
volume in TBI. It also imposes a rather high
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quality requirement on in vivo measurements, for
instance a precision of 1.7% corresponding to
standard deviation is necessary to detect a dose
deficit of 5% in the target volume on the 95%
confidence level.
The American Association of Physicists
in Medicine (AAPM) [AAPM, 1986] answers
pragmatically the question of accuracy. Starting
from the ICRU [lCRU, 1976] recommended
overall accuracy in dose delivery of ±5% the
AAPM suggested to relax this accuracy lewel, if
the prescribed dose is well below the onset of
normal tissue dose is limited locally. AAPM
gives no hints which confidence level is
considered [AAPM, 1986].
Recently Sanchez-Doblado et al.
[Sachez-Doblado et ai, 1995] publisched
guidelines for TBI which are the result of a joint
working party of the Project Managing Group of
the "Treatment of Hematological Malignancies
by Bone Marrow Transplantation from Volumteer
Donors" project sponsored by the European
Union and a dosimetry task group of the
European Late Effects Project Group (EULEP)
and the European group for Blood and Marrow
Transplantation (EBMT). These guidelines
recommend an accuracy as good as possible,
preferably below ±5% (95%confidence level) for
TBI dosimetry. The recommended dose
homogeneity in the transverse section containing
the dose specification point i. e. at mid abdomen
at height of umbilicus as well as along patient's
midline should be within ±10%.
Summarizing these considerations an
overall accuracy in the range of ±3% to ±5%
(I standard deviation) is necessary for in vivo
dosimetry in TBI. We should keep in mind that
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this accuracy is insufficent for the evaluation of
dose and dose distribution according to the
ICRU's recommendations on the 95%
confidence level. If not stated otherwise, errors




The most commonly used detectors for in vivo
dosimetry are ionization chambers,
semiconductor diodes and thermoluminescent
dosimeters (TLD's). Several authors [Quast,
1982; AAPM, 1986; Aukett, 1991; Heukelom et
ai, 1991; Sanchez-Doblado et ai, 1995]
summarized and disscused the problems with
detectors for in vivo dosimetry. Ionization
chambers generally have unwieldy cables and
need a high voltage. Open chambers are
problematic, because body temperatures
influence the readings and the instantaneous
effect is difficult to ases. A temperature increase
of the chamber from 22°C to 37°C requires a
change of the temperature correction factor by
5%. These difficulties are overcome for closed
chambers, although an influence of air
adsorption on the inner chamber walls
theoretically persists. A careful evaluation of the
effects caused by irradiation of the cable and
coupling and monitoring of blank signals are
strongly recommended in any case, especially
when exit doses with low signal levels shall be
recorded.
Semiconductor diodes have smaller
cables, which facilitates their handling but these
detectors show other disadvantages. They tend
to be energy dependent and furthenmore the
response of diodes is dependent on the total
dose received by the diode. Also there is an
effect of temperature and dose per pulse on the
diode's reading. Nevertheless, after an
evaluation of these effects and establishing
related correction factors, these detectors can
be used cuccesfully for in vivo dosimetry as
several authors have demonstrated [Aukett,
1991; Heukelom et ai, 1991; Sanchez-
Doblado,1995]
TLD's have the advantage of being very
small and furthermore, they don't need any
cables. It is relatively easy to fix these detectors
at many points on the patient for entrance and
exit dose measurements. The well known
supralinearity of TLD's is of minor importance for
in vivo dosimetry in TBI, if LiF chips are used
and the doses to be recorded are smaller than
about 1.5 Gy. The energy response should be
considered, especially in the case of large GOCo
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irradiation fields. The predominant disadvantage,
however, is the time required for readout and
dose determination and the delay of results.
Besides these inherent and more
technical limitations of the different dosimeters,
some systematical restrictions of in vivo
dosimetry still remain. One convenient method
for establishing not directly accessible midplane
doses employs entrance and exit dose
measurements. But only in the case of small
children and higher x ray energies these doses
can be calculated by simple averaging of the
measured values. If patients are larger,
corrections taking account for the depth dose
profile(s) must be applied.
The possible lack of scatter at the exit
surface is of additional concern [AAPM, 1986;
Gagnon and Horton, 1979; Lambert et ai, 1983;
Podgorsak et ai, 1985]. It depends on radiation
energy, irradiation geometry, especially the
distance of the patient's exit surface to the wall
or the floor of the irradiation room is important.
Additionally the detectors by theirselves
proViding different scatter conditions influence
the dose evaluation. Typically the corrections are
in the range of 2% to 5%, when the exit surface
is not immediately backed by a scattering
medium, e.g. the couch or the floor of the
irradiation room.
Entrance dose measurements are not
burdenet by such systematical difficulties,
because in TBI a spoiler in front of the patient
provides normally dose build-up for the skin,
which belongs to the target volume. Care shoul~
be taken for the distance between spoiler and
skin. Enrarging this distance results in partial
loss of dose build-up.
Despite all these problems in vivo
dosimetry provides valuable perceptions of dose
and dose distribution in TBI. The main reason is
that, in contrast to normal radiation therapy, the
complex target volume and the scatter
conditions can only roughly be approximated by
phantom measurements. Moreover only now
commercially available computer planning
systems with advanced algorithms seem to be
able to calculate reliable dose distributions in
TBI.
Table 1 summarizes some results of in
vivo dosimetry in TBI at our institution. They
were obtained from 1987 to 1990 for GOCo and
since November 1993 for 10 MV-X. The
numbers represent the mean relative deviations
of measured values versus calculated values in
the thorax for the lateral irradiation fields. During
this irradiation part the patient lies supine and his
upper arm is placed laterally before the lung
dose reduction. If the upper arm's cross section
is too small, additional bolus material is used.
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Table 1
Mean relative deviations of measured values versus calculated values in the thorax. Abbreviations: e: entrance, ex: exit, Ie:
ionization chamber, m: in the middle, behind the arm, I: in the lower part, behind the bolus. Errors represent I standart deviation
of the collective.
Location Dosimeter 6OCo Number 10 MV-X Number
upper arm, e TLD -0,2 ± 2,0 31 -0,9 ± 1,4 22
thorax, e mTLD -6,6±7,1 28 -5,4 ± 3,9 22
IC -4,6 ± 3,1 24




















The dose calculations relay on depth dose
curves, profile?, and absolut dosimetry recorded
under TBI conditions. The patient's anatomy is
evaluated by a series of CT scans and
topograms. Summing up the results of in vivo
measurements, the measured entrance doses
show only small, in clinical practice negligable
deviations from the calculated values. On the
beam exit these deviations become rather large.
They are larger for 60CO than for 10 MV-X,
reflecting the energy dependent distributions of
scattered radiation. The smaller standard
deviations of the higher energy mean values are
in close agreement with this finding.
CONCLUSIONS
In vivo measurements yield valuable
information in TBI. They enable the medical
physicist to minimize dose deviations from the
prescribed values, if technical and systematical
limitations are accounted for. An accurate
control of the radiation dose delivery is an
important prerequisite for evaluating clinical trials
and last but not least for the individual patient
treatments.
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